De Nanteuil G, Gloanec P, Lila C, Portevin B, Boudon A, Rupin A, Verbeuren T J
Division of Medicinal Chemistry, Institut de Recherche Servier, Suresnes, France.
Bioorg Med Chem. 1995 Aug;3(8):1019-24. doi: 10.1016/0968-0896(95)00107-r.
Structural variations of P2 and P3 residues in tripeptidic boroarginine thrombin inhibitors led to compounds with similar potency than reference compound DuP 714, but with enhanced selectivity for thrombin compared to plasmin.
三肽硼酸精氨酸凝血酶抑制剂中P2和P3残基的结构变异产生了与参考化合物DuP 714效力相似,但与纤溶酶相比对凝血酶选择性增强的化合物。